The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -45,540 |
| Depreciation | 1,686 |
| Deferred tax liability | 5 |
| Foreign exchange loss | 3,333 |
| Share-based compensation expense | 3,622 |
| Income tax receivable | -234 |
| Accrued interest receivable | -340 |
| Prepaid expenses and other current assets | 10 |
| Accounts payable | -688 |
| Accrued expenses | 3,686 |
| Long term income tax payable | 78 |
| Net cash used in operating activities | -39,920 |
| Purchase of property and equipment | 289 |
| Net cash used in investing activities | -289 |
| (payment on) proceeds from convertible loan related party-Related Party | -10,000 |
| (payment on) proceeds from convertible loan related party-Nonrelated Party | -250 |
| Net cash (used in) provided by financing activities | -10,250 |
| Effect of foreign exchange rate on cash and cash equivalents | 3,333 |
| Net change in cash and cash equivalents | -47,126 |
| Cash and cash equivalents, beginning of period | 172,677 |
| Cash and cash equivalents, end of period | 125,551 |
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)